1-(tert-butoxycarbonyl)-4(methoxyimino)-2-pyrrolidinecarboxylic acid | 479079-17-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-(tert-butoxycarbonyl)-4(methoxyimino)-2-pyrrolidinecarboxylic acid
• 英文别名: tert-butoxycarbonyl-4-(methoxyimino)-2-Pyrrolidinecarboxylic acid；4-methoxyimino-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid
• CAS: 479079-17-9
• 化学式: C₁₁H₁₈N₂O₅
• 分子量: 258.274
• InChiKey: RPEKVXSOLUPBLF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  88.4
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2,4-噁丁环二酮 、 1-(tert-butoxycarbonyl)-4(methoxyimino)-2-pyrrolidinecarboxylic acid 生成 (2S,4EZ)-1-acetoacetyl-4-(methoxyimino)-N-(1-naphthylmethyl)-2-pyrrolidinecarboxamide 、 1-萘甲基胺
  参考文献：
  名称：

  Pharmaceutically active pyrrolidine derivatives

  摘要：

  本发明涉及式(I)的吡咯烷衍生物。所述化合物优选用作药用活性化合物。具体而言，式(I)的吡咯烷衍生物在治疗和/或预防早产、早产和痛经方面是有用的。特别是，本发明涉及显示出氧催产素受体显著调节作用，特别是拮抗剂活性的吡咯烷衍生物。更具体地，所述化合物在治疗和/或预防由氧催产素介导的疾病状态，包括早产、早产和痛经方面是有用的。本发明还涉及新型吡咯烷衍生物以及其制备方法，其中X从CR6R7、NOR6、NNR6R7组中选择；A从—(C═O)—、—(C═O)—O—、—C(═NH)—、—(C═O)—NH—、—(C═S)—NH、—SO22—、—SO2NH—、—CH2—中选择；B是一个群—(C═O)—NR8R9或表示具有式(a)的杂环残基，其中Q是NR10、O或S；n是选择的整数0、1或2；Y、Z和E与它们连接的2个碳一起形成一个5-6成员芳基或杂芳基环。

  公开号：

  US20030212012A1
• 作为产物：
  描述：

  N-Boc-4-氧代-脯氨酸 、 甲氧基胺盐酸盐 、 三乙胺 在 盐酸 、 乙酸乙酯 、 Brine 、 硫酸酯 作用下， 以 氯仿 、 乙酸乙酯 为溶剂， 以The desired product (5.3 g, 94%) was isolated as a pale yellow oil的产率得到1-(tert-butoxycarbonyl)-4(methoxyimino)-2-pyrrolidinecarboxylic acid
  参考文献：
  名称：

  Pyrrolidine ester derivatives with oxytocin modulating activity

  摘要：

  本发明涉及使用公式（I）的吡咯烷酯治疗和/或预防早产、早产和痛经。特别地，本发明涉及使用公式（I）的吡咯烷酯来调节，尤其是拮抗催产素受体。本发明还涉及新型吡咯烷酯。X选自CR6R7、NOR6、NNR6R7组成的群；R选自C1-C6烷基、C2-C6烯基、C2-C6炔基、饱和或不饱和的3-8环脂肪基，其中可能含有1-3个选自N、O、S、芳基、杂芳基、C1-C6烷基芳基、C1-C6烷基杂芳基的杂原子。R1选自C1-C6烷基、C2-C6烯基、C2-C6炔基、芳基、杂芳基、3-8环脂肪基、酰基、C1-C6烷基芳基、C1-C6烷基杂芳基，所述环脂肪基或芳基或杂芳基基团可以与1-2个进一步的环脂肪基或芳基或杂芳基基团融合。

  公开号：

  US07189754B2

文献信息

• Pyrrolidine oxadiazole-and thiadiazole derivatives
  申请人：——

  公开号：US20040220238A1

  公开（公告）日：2004-11-04

  The present invention is related to pyrrolidine oxadiazole and thiadiazole derivatives for use as pharmaceutically active compounds, as well as pharmaceutical formulations containing such pyrrolidine oxadiazole derivatives. Said pyrrolidine derivatives are useful in the treatment and/or prevention of preterm labor, premature birth and dysmenorrhea. In particular, the present invention is related to pyrrolidine derivatives displaying a substantial modulatory, notably an antagonist activity of the oxytocin receptor. More preferably, said compounds are useful in the treatment and/or prevention of disease states mediated by oxytocin, including preterm labor, premature birth and dysmenorrhea. The present invention is furthermore related to novel pyrrolidine derivatives as well as to methods of their preparation. (I) B is a oxadiazole or thiadiazole group. 1

  本发明涉及吡咯烷氧二唑和噻二唑衍生物，用作药物活性化合物，以及含有此类吡咯烷氧二唑衍生物的制药配方。所述吡咯烷衍生物在治疗和/或预防早产、早产和痛经方面具有用途。特别地，本发明涉及显示出显著调节活性，特别是催产素受体拮抗剂活性的吡咯烷衍生物。更具体地，这些化合物在治疗和/或预防由催产素介导的疾病状态方面具有用途，包括早产、早产和痛经。本发明还涉及新型吡咯烷衍生物及其制备方法。(I) B是氧代二唑或噻二唑基团。
• Pyrrolidine oxadiazole-and thiadiazole oxime derivatives being oxytocin receptor antagonists
  申请人：Schwarz Matthias

  公开号：US20060229343A1

  公开（公告）日：2006-10-12

  The present invention is related to pyrrolidine oxadiazole and thiadiazole derivatives for use as pharmaceutically active compounds, as well as pharmaceutical formulations containing such pyrrolidine oxadiazole derivatives. Said pyrrolidine derivatives are useful in the treatment and/or prevention of preterm labor, premature birth and dysmenorrhea. In particular, the present invention is related to pyrrolidine derivatives displaying a substantial modulatory, notably an antagonist activity of the oxytocin receptor. More preferably, said compounds are useful in the treatment and/or prevention of disease states mediated by oxytocin, including preterm labor, premature birth and dysmenorrhea. The present invention is furthermore related to novel pyrrolidine derivatives as well as to methods of their preparation. B is a oxadiazole or thiadiazole group.

  本发明涉及吡咯烷氧噻二唑和噻二唑衍生物，用作药物活性化合物，以及包含此类吡咯烷氧噻二唑衍生物的制药配方。所述吡咯烷衍生物在治疗和/或预防早产、早产和痛经方面具有用途。特别是，本发明涉及显示出 oxytocin 受体的重要调节作用，特别是拮抗剂活性的吡咯烷衍生物。更具体地说，所述化合物在治疗和/或预防由 oxytocin 介导的疾病状态方面具有用途，包括早产、早产和痛经。本发明还涉及新的吡咯烷衍生物以及它们的制备方法。B 是一个氧噻二唑或噻二唑基团。
• Pyrrolidine oxadiazole- and thiadiazole oxime derivatives being oxytocin receptor antagonists
  申请人：Applied Research Systems ARS Holding N.V.

  公开号：US07115639B2

  公开（公告）日：2006-10-03

  The present invention is related to pyrrolidine oxadiazole and thiadiazole derivatives for use as pharmaceutically active compounds, as well as pharmaceutical formulations containing such pyrrolidine oxadiazole derivatives. Said pyrrolidine derivatives are useful in the treatment and/or prevention of preterm labor, premature birth and dysmenorrhea. In particular, the present invention is related to pyrrolidine derivatives displaying a substantial modulatory, notably an antagonist activity of the oxytocin receptor. More preferably, said compounds are useful in the treatment and/or prevention of disease states mediated by oxytocin, including preterm labor, premature birth and dysmenorrhea. The present invention is furthermore related to novel pyrrolidine derivatives as well as to methods of their preparation. (I) B is a oxadiazole or thiadiazole group

  本发明涉及吡咯烷噁唑和噻唑衍生物，用作药物活性化合物，以及含有此类吡咯烷噁唑衍生物的制药配方。所述吡咯烷衍生物在治疗和/或预防早产、早产和痛经方面有用。特别地，本发明涉及显示 oxytocin 受体的显著调节作用，特别是拮抗剂活性的吡咯烷衍生物。更优选地，这些化合物在治疗和/或预防由 oxytocin 介导的疾病状态，包括早产、早产和痛经方面有用。本发明还涉及新型吡咯烷衍生物以及它们的制备方法。(I) B 是噁唑或噻唑基团。
• Pharmaceutically active pyrrolidine derivatives
  申请人：——

  公开号：US20030212012A1

  公开（公告）日：2003-11-13

  The present invention is related to pyrrolidine derivatives of formula (I). Said 1 compounds are preferably for use as pharmaceutically active compounds. Specifically, pyrrolidine derivatives of formula (I) are useful in the treatment and/or prevention of premature labor, premature birth and dysmenorrhea. In particular, the present invention is related to pyrrolidine derivatives displaying a substantial modulatory, notably an antagonist activity of the oxytocin receptor. More preferably, said compounds are useful in the treatment and/or prevention of disease states mediated by oxytocin, including premature labor, premature birth and dysmenorrhea. The present invention is furthermore related to novel pyrrolidine derivatives as well as to methods of their preparation, wherein X is selected from the group consisting of CR6R7, NOR6, NNR6R7; A is selected from the group consisting of —(C═O)—, —(C═O)—O—, —C(═NH)—, —(C═O)—NH—, —(C═S)—NH, —SO22—, —SO2NH—, —CH2—,B is either a group —(C═O)—NR8R9 or represents a heterocyclic residue having the formula (a) wherein Q is NR10, O or S; n is an integer selected of 0, 1 or 2; Y, Z and E form together with the 2 carbons to which they are attached a 5-6 membered aryl or heteroaryl ring.

  本发明涉及式(I)的吡咯烷衍生物。所述化合物优选用作药用活性化合物。具体而言，式(I)的吡咯烷衍生物在治疗和/或预防早产、早产和痛经方面是有用的。特别是，本发明涉及显示出氧催产素受体显著调节作用，特别是拮抗剂活性的吡咯烷衍生物。更具体地，所述化合物在治疗和/或预防由氧催产素介导的疾病状态，包括早产、早产和痛经方面是有用的。本发明还涉及新型吡咯烷衍生物以及其制备方法，其中X从CR6R7、NOR6、NNR6R7组中选择；A从—(C═O)—、—(C═O)—O—、—C(═NH)—、—(C═O)—NH—、—(C═S)—NH、—SO22—、—SO2NH—、—CH2—中选择；B是一个群—(C═O)—NR8R9或表示具有式(a)的杂环残基，其中Q是NR10、O或S；n是选择的整数0、1或2；Y、Z和E与它们连接的2个碳一起形成一个5-6成员芳基或杂芳基环。
• Pyrrolidine ester derivatives with oxytocin modulating activity
  申请人：Applied Research Systems ARS Holding NV

  公开号：US07189754B2

  公开（公告）日：2007-03-13

  The present invention is related to the use of pyrrolidine esters of formula (I) for the treatment and/or prevention of premature labor, premature birth and dysmenorrhea. In particular, the present invention is related to the use of pyrrolidine esters of formula (I) to modulate, notably to antagonize the oxytocin receptor. The present invention is furthermore related to novel pyrrolidine esters. X is selected from the group consisting of CR6R7, NOR6, NNR6R7; R is selected from the group comprising or consisting of C1–C6 alkyl, C2–C6 alkenyl, C2–C6 alkynyl, saturated or unsaturated 3–8-membered cycloalkyl which may contain 1 to 3 heteroatoms selected of N, O, S, aryl, heteroaryl, C1–C6-alkyl aryl, C1–C6-alkyl heteroaryl. R1 is selected from the group comprising or consisting of C1–C6-alkyl, C2–C6-alkenyl, C2–C6-alkynyl, aryl, heteroaryl, 3–8-membered cycloalkyl, acyl, C1–C6-alkyl aryl, C1–C6-alkyl heteroaryl, said cycloalkyl or aryl or heteroaryl groups may be fused with 1–2 further cycloalkyl or aryl or heteroaryl group

  本发明涉及使用公式（I）的吡咯烷酯治疗和/或预防早产、早产和痛经。特别地，本发明涉及使用公式（I）的吡咯烷酯来调节，尤其是拮抗催产素受体。本发明还涉及新型吡咯烷酯。X选自CR6R7、NOR6、NNR6R7组成的群；R选自C1-C6烷基、C2-C6烯基、C2-C6炔基、饱和或不饱和的3-8环脂肪基，其中可能含有1-3个选自N、O、S、芳基、杂芳基、C1-C6烷基芳基、C1-C6烷基杂芳基的杂原子。R1选自C1-C6烷基、C2-C6烯基、C2-C6炔基、芳基、杂芳基、3-8环脂肪基、酰基、C1-C6烷基芳基、C1-C6烷基杂芳基，所述环脂肪基或芳基或杂芳基基团可以与1-2个进一步的环脂肪基或芳基或杂芳基基团融合。